Dengue Antibody-Dependent Enhancement: Knowns and Unknowns
- PMID: 26104444
- DOI: 10.1128/microbiolspec.AID-0022-2014
Dengue Antibody-Dependent Enhancement: Knowns and Unknowns
Abstract
Dengue provides the most abundant example in human medicine and the greatest human illness burden caused by the phenomenon of intrinsic antibody-dependent infection enhancement (iADE). In this immunopathological phenomenon infection of monocytes or macrophages using infectious immune complexes suppresses innate antiviral systems, permitting logarithmic intracellular growth of dengue virus. The four dengue viruses evolved from a common ancestor yet retain similar ecology and pathogenicity, but although infection with one virus provides short-term cross-protection against infection with a different type, millions of secondary dengue infections occur worldwide each year. When individuals are infected in the virtual absence of cross-protective dengue antibodies, the dengue vascular permeability syndrome (DVPS) may ensue. This occurs in around 2 to 4% of second heterotypic dengue infections. A complete understanding of the biologic mechanism of iADE, dengue biology, and the mechanism of host responses to dengue infection should lead to a comprehensive and complete understanding of the pathogenesis of DVPS. A crucial emphasis must be placed on understanding ADE. Clinical and epidemiological observations of DVPS define the research questions and provide research parameters. This article will review knowledge related to dengue ADE and point to areas where there has been little research progress. These observations relate to the two stages of dengue illnesses: afferent phenomena are those that promote the success of the microorganism to infect and survive; efferent phenomena are those mounted by the host to inhibit infection and replication and to eliminate the infectious agent and infected tissues. Data will be discussed as "knowns" and "unknowns."
Similar articles
-
Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice.J Virol. 2015 Jun;89(11):5847-61. doi: 10.1128/JVI.00216-15. Epub 2015 Mar 18. J Virol. 2015. PMID: 25787279 Free PMC article.
-
Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.Front Immunol. 2018 Apr 23;9:597. doi: 10.3389/fimmu.2018.00597. eCollection 2018. Front Immunol. 2018. PMID: 29740424 Free PMC article. Review.
-
Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection.mBio. 2015 Sep 15;6(5):e01316-15. doi: 10.1128/mBio.01316-15. mBio. 2015. PMID: 26374123 Free PMC article.
-
Antibody-dependent enhancement of dengue virus infection in vitro by undiluted sera from monkeys infected with heterotypic dengue virus.Arch Virol. 2010 Oct;155(10):1617-24. doi: 10.1007/s00705-010-0741-x. Epub 2010 Jul 20. Arch Virol. 2010. PMID: 20644969
-
Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development.Expert Rev Vaccines. 2016;15(4):467-82. doi: 10.1586/14760584.2016.1121814. Epub 2015 Dec 15. Expert Rev Vaccines. 2016. PMID: 26577689 Review.
Cited by
-
Genomic sequencing and neutralizing serological profiles during acute dengue infection: A 2017 cohort study in Nepal.PLOS Glob Public Health. 2024 Nov 13;4(11):e0002966. doi: 10.1371/journal.pgph.0002966. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 39535994 Free PMC article.
-
Potential role of heterologous flavivirus immunity in preventing urban transmission of yellow fever virus.Nat Commun. 2024 Nov 10;15(1):9728. doi: 10.1038/s41467-024-54146-9. Nat Commun. 2024. PMID: 39523371 Free PMC article.
-
The role of antibody-dependent enhancement in dengue vaccination.Trop Dis Travel Med Vaccines. 2024 Nov 1;10(1):22. doi: 10.1186/s40794-024-00231-2. Trop Dis Travel Med Vaccines. 2024. PMID: 39482727 Free PMC article.
-
Dengue virus surveillance in Nepal yields the first on-site whole genome sequences of isolates from the 2022 outbreak.BMC Genomics. 2024 Oct 24;25(1):998. doi: 10.1186/s12864-024-10879-x. BMC Genomics. 2024. PMID: 39449117 Free PMC article.
-
Modelling the mechanisms of antibody mixtures in viral infections: the cases of sequential homologous and heterologous dengue infections.J R Soc Interface. 2024 Oct;21(219):20240182. doi: 10.1098/rsif.2024.0182. Epub 2024 Oct 16. J R Soc Interface. 2024. PMID: 39406340
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical